Predicting Response to KRAS G12C Inhibitors in NSCLC
February 4, 2025
-
2 min
5 Key Takeaways
-
1
Proximity ligation assay developed to measure RAS and RAF protein interactions in lung cancer cells.
-
2
Stronger RAS-RAF protein interactions correlated with higher response to KRAS G12C inhibitors.
-
3
EGFR activity not predictive of response to KRAS G12C inhibitors.
-
4
Findings could revolutionize personalized cancer treatment.
-
5
Research supported by the National Institutes of Health, the Moffitt Lung Cancer Center of Excellence, and Revolution Medicines.
A recent study published in Clinical Cancer Research revealed that researchers have developed a proximity ligation assay to measure RAS and RAF protein interactions in cancer cells, offering insights into treatment effectiveness for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC). The study found that tumors with stronger RAS-RAF protein interactions had higher levels of active RAS signaling and were more likely to respond to KRAS G12C inhibitors. This novel method could revolutionize personalized cancer treatment, providing more accurate biomarkers for treatment response and potentially leading to better outcomes for patients.
Listen Tab content
